Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: Immune checkpoint inhibition (ICI) alone is not active in mismatch repair–proficient (MMR-P) metastatic colorectal cancer (mCRC), nor does radiotherapy alone result in objective systemic benefit. However, combined radiotherapy plus ICI can induce systemic antitumor immunity in preclinical and clinical models. Patients and Methods: In this single-center, phase II study, patients with chemotherapy-refractory MMR-P mCRC received durvalumab 1,500 mg plus tremelimumab 75 mg every 4 weeks plus radiotherapy. The primary endpoint was objective response rate (ORR) in nonirradiated lesions. Treatment and efficacy were correlated with peripheral immune cell profiles. Results: We enrolled 24 patients, and report outcomes after a median follow-up of 21.8 (range: 15.9–26.3) months. The ORR was 8.3% (2 patients) [95% confidence interval (CI), 1.0–27.0]. The median progression-free survival was 1.8 (95% CI, 1.7–1.9) months, median overall survival was 11.4 (95% CI, 10.1–17.4) months. Twenty five percent of patients (n = 6) had treatment-related grade 3–4 adverse events. We observed increased circulating CD8+ T lymphocyte activation, differentiation, and proliferation in patients with objective response. Conclusions: This combination of radiotherapy plus ICI study did not meet the prespecified endpoint criteria to be considered worthwhile for further study. However, rare instances of systemic immune augmentation and regression in nonirradiated lesions were observed (an abscopal response). Combination durvalumab and tremelimumab plus radiotherapy is feasible in MMR-P mCRC with a manageable safety profile. Further studies of novel immunotherapy combinations, and identification of biomarkers predictive of abscopal response are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 6×
“org Clin Cancer Res; 27(8) April 15, 2021 2201”
BackgroundInfluentialEng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577
Self-citation
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67
Gandini, A., Puglisi, S., Pirrone, C., Martelli, V., Catalano, F., Nardin, S., Seeber, A., Puccini, A., & Sciallero, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1161048 · Cited by 42
Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40
“Interestingly, some of these studies have shown that certain patients demonstrate an abscopal response, defined as a response in non-irradiated distant tumors after receiving the combination therapy of radiation to a targeted tumor and ICIs [57,58].”
BackgroundCurrent and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
“…most clinical trials that evaluate the efficacy of ICB in pMMR/MSS CRC combine cytotoxic and/or other targeted therapies together with ICB, 141–143 and it seems plausible that strategies that increase the susceptibility of tumour towards conventional therapies will be beneficial for…”
Metadata
- Authors
- Segal, N. H., Cercek, A., Ku, G., Wu, A. J., Rimner, A., Khalil, D. N., Reidy-Lagunes, D., Cuaron, J., Yang, T. J., Weiser, M. R., Romesser, P. B., Stadler, Z. K., Varghese, A. M., Ganesh, K., Yaeger, R., Connell, L. C., Faleck, D., Abou-Alfa, G. K., Mcauliffe, K. C., Vaiskauskas, P., Solter, M. L., Ogle, M., Adamow, M. J., Holland, A., Vedantam, P., Wong, P., Merghoub, T., Vakiani, E., Hollmann, T. J., Juluru, K., Chou, J. F., Capanu, M., Erinjeri, J., Solomon, S., Yamada, Y., Kemeny, N., Crane, C. H., & Saltz, L. B.
- Venue
- Clinical Cancer Research
- Published
- 2021-01-27
- Volume
- 27
- Issue
- 8
- Pages
- 2200-2208
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3125474097
- Cited by
- 84
- References
- 6
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2474
- The paper
- Segal, N. H., Cercek, A., Ku, G., Wu, A. J., Rimner, A., Khalil, D. N., Reidy-Lagunes, D., Cuaron, J., Yang, T. J., Weiser, M. R., Romesser, P. B., Stadler, Z. K., Varghese, A. M., Ganesh, K., Yaeger, R., Connell, L. C., Faleck, D., Abou-Alfa, G. K., Mcauliffe, K. C., . . . Saltz, L. B. (2021). Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.